Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!
Expand chart
Data: KFF September 2021 Vaccine Monitor; Chart: Jacque Schrag/Axios

Conservative media sometimes blame the problem of the unvaccinated on people of color, but the data show vaccine resistance is mostly about red America and younger adults now.

Why it matters: The numbers show a much different story about where we still need to be focusing our vaccination efforts.

By the numbers: 59% of the unvaccinated are Republicans, 64% are white and 46% have a high school education or less. More than half of the unvaccinated live in suburbs with another 27% living in rural areas.

  • By contrast, 14% are Black, 16% are Hispanic, and 27% live in cities.  

Between the lines: These unvaccinated adults tend towards COVID denialism and often see their decision not to get the vaccination as an expression of their personal freedom.

  • When they do get vaccinated, persuasion and information are not moving them nearly as much as seeing family members, friends and neighbors get sick, go to the hospital, and die, and seeing local news reports about their local hospitals overwhelmed with COVID patients.
  • Employer mandates are another reality influencing their behavior as companies who have instituted them report their employees are choosing paychecks over their vaccine resistance.   

We can't know what vaccine resistance in red America would look like today were it not for the efforts of former President Trump to deny the seriousness of the pandemic and of several Republican governors to echo similar views and stand in the way of public health measures like mask orders or mandates.  

The intrigue: Then there is another group who also make up a significant share of the unvaccinated: younger adults. Nearly 40% of the unvaccinated are 30–49 years old and another 27% are 18–29.

  • These are the groups who get a lot of their COVID information from social media and are particularly prone to myths and misinformation. They will make the critical decisions about vaccination of the next big group of unvaccinated Americans, children.
  • Nearly half (48%) of parents of children ages 12–17 say their child has received at least one dose of a vaccine.
  • With Pfizer's clinical trials showing their COVID-19 vaccine is safe and effective for children ages five to eleven, at this early stage about a third of parents (34%) say they will vaccinate their 5-to-11-year-old child "right away" once a vaccine is authorized for their age group.  

It is unclear whether unvaccinated parents will be equally cautious about vaccinating their kids or more likely to put their qualms about vaccination aside to protect them as they see more and more stories about children's hospitals filling up and schools closing as children and staff are infected.

The bottom line: Equity requires a continuing heavy emphasis on vaccination in communities of color where there is a disproportionate risk for bad outcomes from infection with COVID and historical structural inequities.

  • However, if the vaccination effort is to go where the bulk of the problem is, that's now mostly red America, younger adults and their children.

Go deeper

16 hours ago - Health

FDA authorizes mix-and-match for COVID booster shots

Photo: Francine Orr/Los Angeles Times via Getty Images

The Food and Drug Administration (FDA) on Wednesday gave its approval for Americans to get booster shots that are different from the COVID vaccine they initially received.

Why it matters: The recommendation from the FDA, which also authorized booster shots for people who received Moderna and Johnson & Johnson vaccines on Wednesday, paves the way for an expansion of booster shots.

Oct 20, 2021 - Health

The global coronavirus vaccine gap

Illustration: Shoshana Gordon/Axios

The world still needs more coronavirus vaccines, particularly low-income countries. Pressure is increasing on the Biden administration to close the gap — and the Biden administration, in turn, is pushing Moderna to fill it.

Why it matters: Getting global vaccination rates as high as possible isn't just a humanitarian effort; it also reduces the risk of vaccine-resistant variants emerging.

Oct 20, 2021 - World

Gates Foundation to send $120 million of COVID antiviral pills to lower-income countries

Illustration: Aïda Amer/Axios

The Bill & Melinda Gates Foundation said Wednesday it will funnel up to $120 million worth of molnupiravir, an experimental antiviral COVID-19 treatment from Merck, to lower-income countries.

Why it matters: The foundation and others see the antiviral pill's promising results against severe COVID-19 and easy distribution as a way to target countries with low vaccination rates.